MA47458A - Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer - Google Patents
Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancerInfo
- Publication number
- MA47458A MA47458A MA047458A MA47458A MA47458A MA 47458 A MA47458 A MA 47458A MA 047458 A MA047458 A MA 047458A MA 47458 A MA47458 A MA 47458A MA 47458 A MA47458 A MA 47458A
- Authority
- MA
- Morocco
- Prior art keywords
- hydrocarbylsulfonyl
- pyridines
- substitution
- cancer treatment
- cancer
- Prior art date
Links
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455641P | 2017-02-07 | 2017-02-07 | |
| US201762594794P | 2017-12-05 | 2017-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47458A true MA47458A (fr) | 2019-12-18 |
Family
ID=61274298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047458A MA47458A (fr) | 2017-02-07 | 2018-02-07 | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11161815B2 (fr) |
| EP (1) | EP3580203A1 (fr) |
| JP (1) | JP7229176B2 (fr) |
| KR (1) | KR20190115014A (fr) |
| CN (1) | CN110382464A (fr) |
| AU (1) | AU2018218522B2 (fr) |
| BR (1) | BR112019016248A2 (fr) |
| CA (1) | CA3051539A1 (fr) |
| MA (1) | MA47458A (fr) |
| MX (1) | MX392900B (fr) |
| RU (1) | RU2019128063A (fr) |
| WO (1) | WO2018146472A1 (fr) |
| ZA (1) | ZA201904966B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| KR20190115012A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로사이클릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| KR20190115013A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로아릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| EP3580203A1 (fr) * | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer |
| MX2019009356A (es) | 2017-02-07 | 2019-09-19 | Oblique Therapeutics Ab | Sulfinilpiridinas y su uso en el tratamiento del cancer. |
| CA3091085A1 (fr) * | 2018-02-12 | 2019-08-15 | Cinda Pharma Ab | Inhibiteurs de la thioredoxine reductase a utiliser dans le traitement du cancer |
| EP4201929B1 (fr) * | 2021-12-24 | 2024-08-14 | geneXplain GmbH | Inhibiteurs quinoxaline de thiorédoxine réductase |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031173B1 (fr) | 1979-12-19 | 1983-09-14 | Duphar International Research B.V | Nitrothiophènes, procédé pour leur préparation, ainsi que compositions fongicides et/ou bactéricides les contenant |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| JPS63166865A (ja) * | 1986-12-22 | 1988-07-11 | バイエル・アクチエンゲゼルシヤフト | 置換されたフエノキシピリジン類 |
| DE3729071A1 (de) * | 1986-12-22 | 1988-06-30 | Bayer Ag | Substituierte phenoxypyridine |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| US5945425A (en) | 1994-04-29 | 1999-08-31 | G.D. Searle & Co. | Method of using (H+ /K+)ATPase inhibitors as antiviral agents |
| DE19531148A1 (de) * | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| EP0850223A1 (fr) | 1995-08-24 | 1998-07-01 | Basf Aktiengesellschaft | Composes n-heterocycliques, produits intermediaires utilises pour les preparer, agents les contenant et utilisation pour lutter contre des champignons nuisibles |
| DE19531348A1 (de) | 1995-08-25 | 1997-02-27 | Gsf Forschungszentrum Umwelt | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo |
| US6191280B1 (en) | 1997-05-30 | 2001-02-20 | Basf Aktiengesellschaft | Method for producing substituted thiopyridines |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| WO1999018096A1 (fr) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibiteurs de la prenyl-proteine transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| ATE236136T1 (de) | 1998-01-16 | 2003-04-15 | Hoffmann La Roche | Benzosulfonderivate |
| ES2254385T3 (es) | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003068744A1 (fr) | 2002-02-18 | 2003-08-21 | Ishihara Sangyo Kaisha, Ltd. | Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives |
| US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| WO2005007621A2 (fr) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de ligase d'ubiquitine |
| HRP20090093T3 (en) | 2004-06-04 | 2009-03-31 | Arena Pharmaceuticals Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (fr) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Procédés d'identification de modulateurs de bromodomaines |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP1976495A2 (fr) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Composes agissant sur le transporteur de la serotonine |
| CA2647338A1 (fr) | 2006-04-28 | 2007-11-08 | Avexa Limited | Inhibiteurs de l'integrase-3 |
| EP2061472A4 (fr) * | 2006-05-22 | 2010-12-22 | Thioredoxin Systems Ab | Inhibiteurs de thioredoxine reductase bacterienne et procédés d'utilisation afférents |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2010007756A1 (fr) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Dérivé de pyridine ayant une activité d'inhibition de la ttk |
| CN101723932B (zh) * | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| US9421211B2 (en) | 2009-05-28 | 2016-08-23 | President And Fellows Of Harvard College | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation |
| NZ598262A (en) | 2009-08-17 | 2014-05-30 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| WO2011099502A1 (fr) | 2010-02-10 | 2011-08-18 | 公立大学法人横浜市立大学 | Utilisation d'un composé se liant à msin3b qui se lie, de façon spécifique, au facteur silenceur de la spécification neuronale nrsf |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| WO2012025638A1 (fr) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Inhibiteurs sélectifs de la 17-bêta-hydroxystéroïde déshydrogénase de type 1 |
| AU2013216885B2 (en) | 2012-02-10 | 2017-08-03 | The Board Of Regents Of The University Of Texas System | Modulators of exchange proteins directly activated by cAMP (EPACs) |
| US8946418B1 (en) | 2013-07-10 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN104672241B (zh) | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) * | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| KR20190115013A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로아릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| EP3580203A1 (fr) * | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer |
| KR20190115012A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로사이클릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| MX2019009356A (es) * | 2017-02-07 | 2019-09-19 | Oblique Therapeutics Ab | Sulfinilpiridinas y su uso en el tratamiento del cancer. |
-
2018
- 2018-02-07 EP EP18707131.1A patent/EP3580203A1/fr not_active Withdrawn
- 2018-02-07 CN CN201880010169.1A patent/CN110382464A/zh active Pending
- 2018-02-07 JP JP2019563699A patent/JP7229176B2/ja active Active
- 2018-02-07 WO PCT/GB2018/050346 patent/WO2018146472A1/fr not_active Ceased
- 2018-02-07 RU RU2019128063A patent/RU2019128063A/ru unknown
- 2018-02-07 KR KR1020197024697A patent/KR20190115014A/ko not_active Ceased
- 2018-02-07 MX MX2019009266A patent/MX392900B/es unknown
- 2018-02-07 AU AU2018218522A patent/AU2018218522B2/en not_active Ceased
- 2018-02-07 CA CA3051539A patent/CA3051539A1/fr active Pending
- 2018-02-07 US US16/484,057 patent/US11161815B2/en not_active Expired - Fee Related
- 2018-02-07 MA MA047458A patent/MA47458A/fr unknown
- 2018-02-07 BR BR112019016248A patent/BR112019016248A2/pt not_active IP Right Cessation
-
2019
- 2019-07-29 ZA ZA2019/04966A patent/ZA201904966B/en unknown
-
2021
- 2021-10-29 US US17/514,288 patent/US20220119348A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019128063A (ru) | 2021-03-09 |
| JP7229176B2 (ja) | 2023-02-27 |
| US20220119348A1 (en) | 2022-04-21 |
| JP2020506970A (ja) | 2020-03-05 |
| KR20190115014A (ko) | 2019-10-10 |
| MX392900B (es) | 2025-03-24 |
| EP3580203A1 (fr) | 2019-12-18 |
| US20200239417A1 (en) | 2020-07-30 |
| RU2019128063A3 (fr) | 2021-05-21 |
| ZA201904966B (en) | 2023-12-20 |
| BR112019016248A2 (pt) | 2020-04-14 |
| WO2018146472A1 (fr) | 2018-08-16 |
| AU2018218522B2 (en) | 2021-08-05 |
| CA3051539A1 (fr) | 2018-08-16 |
| AU2018218522A1 (en) | 2019-08-15 |
| US11161815B2 (en) | 2021-11-02 |
| CN110382464A (zh) | 2019-10-25 |
| MX2019009266A (es) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43163A (fr) | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer | |
| MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
| MA47452A (fr) | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA52886A (fr) | Composés de purinone et leur utilisation dans le traitement du cancer | |
| MA47451A (fr) | Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer | |
| SI3661954T1 (sl) | Muteini interlevkina-21 in postopki zdravljenja | |
| MA42915A (fr) | Pyridines et leur utilisation dans le traitement du cancer | |
| EP3673947A4 (fr) | Cathéter et ensemble cathéter | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| EP3431102A4 (fr) | Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer | |
| IL258706A (en) | Ametropia treatment tracking methods and system | |
| EP2831278A4 (fr) | Aptamères dirigés contre pdgf et vegf et leur utilisation dans le traitement d'états à médiation par pdgf et vegf | |
| MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer | |
| MA41316A (fr) | Gènes de détermination du sexe et leur utilisation en reproduction | |
| SI3319612T1 (sl) | Oksisteroli in postopki za uporabo le-teh | |
| MA47408A (fr) | Traitement du cancer | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| MA41587A (fr) | N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique | |
| EP3258964A4 (fr) | Détection et traitement de tumeurs malignes dans le snc | |
| MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules | |
| EP3713289A4 (fr) | Procédé de traitement de requêtes, et entité correspondante | |
| EP3733175A4 (fr) | Traitement du cancer | |
| ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| EP3298167A4 (fr) | Profils d'expression génique et utilisations de ceux-ci dans le cancer du sein | |
| EP3431517A4 (fr) | Copolymère, et agent de traitement de surface |